SC dismisses plea against Ranbaxy

The writ petition had been filed purportedly to enforce fundamental right under Article 21 right to life. However,no material has been placed before the court to show that the drugs manufactured by any of the manufacturing units of Ranbaxy in India are sub-standard or adulterated and further that such drugs,which are prohibited,are being sold by Ranbaxy in India, said the bench.

While giving a liberty to petitioner ML Sharma,a lawyer,to file a fresh petition if he could bring on record adequate material to substantiate the accusations,the court made it clear that its jurisdiction could be invoked not by what happened in the US but only when it could be shown that companys drugs in India threatened peoples health.